Decernotinib

• Description :

  Decernotinib is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

• Product Name Alternative :

  VX-509; VRT-831509

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  JAK

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Decernotinib.html

• Purity :

  99.91

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  C[C@](C(NCC(F)(F)F)=O)(CC)NC1=NC(C2=CNC3=NC=CC=C32)=NC=C1

• Molecular Formula :

  C18H19F3N6O

• Molecular Weight :

  392.38

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Mahajan S, et al. VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 Mar 11. pii: jpet.114.221176.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  JAK1; JAK2; JAK3; Tyk2

• CAS Number :

  [944842-54-0]